Tofacitinib May Have Beneficial Effect on JIA Patient Growth
A recent study suggests that long-term treatment with tofacitinib may positively influence growth in patients with juvenile idiopathic arthritis (JIA). The analysis showed that patients aged 12 years or younger experienced greater than expected height velocities, while those older than 12 had expected growth rates. Overall, the findings indicate that tofacitinib treatment can lead to normal growth patterns in JIA patients over time.
- ▪The study included 225 patients aged 2 to less than 18 years with JIA who received continuous tofacitinib treatment.
- ▪Height velocities were greater than expected for patients aged 12 years or younger during treatment.
- ▪An increase in height Z score was detected in pubertal patients with a baseline height Z score less than -1.0 after 24 months of treatment.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/tofacitinib-may-have-beneficial-effect-growth-patients-jia-2026a1000gyn?src=rss |
| Publication time | Mon, 25 May 2026 03:16:57 EDT |
| Retrieval time | 2026-05-25T07:37:36.533Z |
| Last seen | 2026-05-25T07:37:36.533Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | O592rF3-hiwv |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Patients with juvenile idiopathic arthritis (JIA) who received long-term tofacitinib treatment had height velocities that appeared greater than expected in those aged 12 years or younger and were as expected in those older than 12 years, relative to reference populations.METHODOLOGY:Researchers conducted a post hoc analysis to evaluate the long-term impact of tofacitinib on height and height velocity in patients with JIA.The analysis included 225 patients aged 2 years to less than 18 years with JIA (median age, 13.0 years; 75.1% girls), primarily with polyarticular course JIA, who received continuous tofacitinib treatment across three studies in the JIA development program conducted in 22 countries.Patients received open-label tofacitinib 5 mg twice daily or an equivalent…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
